Dr He and colleagues compared the effectiveness of an intensive BP intervention to usual care on the risk reduction of dementia in patients with hypertension in a cluster-randomised trial. The 33,995 participants with hypertension from 326 rural Chinese villages were randomised 1:1 to usual care or an intensive intervention. The experimental intervention included doctor-initiated titration of anti-hypertensive drugs, the deliverance of discounted and free medications to patients, lifestyle interventions, education on BP monitoring, and medication adherence instructions. The primary outcome was all-cause dementia at 48 months.
“In the usual-care arm, the systolic BP had dropped with a mean 7.2 mmHg, and in the experimental arm, this measure was reduced with a mean 29.2 mmHg,” said Dr He. For diastolic BP the corresponding rates were -6.1 mmHg and -15.4 mmHg. In addition, 67.7% of the participants in the intervention arm were normotensive at 48 months compared with 15.0% in the usual-care arm (P<0.0001). Not surprisingly, those in the experimental arm were on a higher number of anti-hypertensive agents (mean 3.0 vs 1.2; P<0.0001). “Importantly, the primary outcome was met, with an annual rate of 1.12% of all-cause dementia in the experimental arm and a rate of 1.31% in the control arm (RR 0.85; 95% CI 0.76–0.95; P=0.0035), representing a 15% reduction,” according to Dr He.
- He J, et al. Effectiveness of blood pressure lowering intervention on risk of total dementia among patients with hypertension: a cluster-randomised effectiveness trial. LB04, AHA Scientific Sessions 2023, 10–12 November, Philadelphia, USA.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« BP intervention saves lives of hypertensive pregnant women Next Article
Dapagliflozin improves cardiometabolic outcomes in MI »
« BP intervention saves lives of hypertensive pregnant women Next Article
Dapagliflozin improves cardiometabolic outcomes in MI »
Table of Contents: AHA 2023
Featured articles
Successful results for semaglutide in highly anticipated SELECT trial
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Online First
Pemafibrate reduces microvascular complications of PAD and T2D
Encouraging data for lepodisiran as Lp(a) lowering therapy
Nicotinamide riboside may improve walking function in PAD
Successful results for semaglutide in highly anticipated SELECT trial
Gene editing may change treatment landscape of hypercholesterolaemia
Biannual zilebesiran associated with substantial BP reductions
ARTESIA: How useful is anticoagulation in subclinical AF?
MINT: Liberal or restrictive transfusion strategy in MI with anaemia?
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
ORBITA-2 confirms PCI as alternative to anti-anginal drugs in stable angina
Dapagliflozin improves cardiometabolic outcomes in MI
BP intervention saves lives of hypertensive pregnant women
Related Articles
November 15, 2023
ARTESIA: How useful is anticoagulation in subclinical AF?
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy